Market accessCompany release

CVRx cuts 2026 revenue guidance after third-quarter sales fall 6% to $13.8M

🇺🇸 CVRx, Inc. (CVRX) · Thu 05 Nov 2026

The Barostim maker lowered its full-year outlook, pointing to weaker sales force productivity and a drawn-out dispute with a major payer, despite a second Medicare Advantage coverage policy.

CVRx reported third-quarter 2026 results on 5 November, with revenue of $13.8M, a 6% decline, and a net loss of $14.2M. The company markets Barostim, a neuromodulation device for heart failure.

The company lowered its full-year 2026 revenue guidance to $56-57M, down from the $58-60M range it had previously given. It attributed the cut to lower sales force productivity and a prolonged challenge with a major payer.

There was some progress on coverage. A second Medicare Advantage provider issued a coverage policy for Barostim effective 17 July 2026. Together, the two policies now cover about 21% of Medicare Advantage enrollment, according to the company.

The summary provided does not detail which payer is at the centre of the prolonged challenge, nor the terms of the new coverage policy, so the extent to which these policies offset the payer difficulties is not clear from the available information.

What it means for your team

  • Market-access teams in the device sector should note that individual payer policies can take time to translate into sales, as shown by CVRx's guidance cut despite a new Medicare Advantage policy.
  • The two Medicare Advantage policies reach roughly 21% of enrollment, leaving most of that market without a Barostim-specific policy based on the figures reported.
  • Teams tracking reimbursement for implantable neuromodulation should watch for further payer decisions, as the company has tied its revised outlook partly to a continuing payer issue.

Company's press release (SEC filing): CVRx, Inc. ↗

Article written by VigiEye from the official source (CVRx, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Market access All →